Qiagen : Q1 2023 review
>Solid start to 2023 despite severe headwinds - Qiagen’s Q1 revenues of $ 485m (-22.8% y-o-y) were in line with our and the consensus’ expectations. Revenues development at CER was -20%, while forex translated into a headwind of 300bp. COVID-related revenues were down 76% CER to $ 52m in the quarter. Correspondingly, non-COVID product groups were up 12% CER in the quarter, which we rateas positive. Adjusted EBIT of $ 124m (-46.5% y-o-y, margin 25.6%) was -5%/-2% ...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.